Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alcon has received approval from the Ministry of Health, Labor and Welfare in Japan to market its leading eye allergy drug Patanol for allergic conjunctivitis.
Subscribe to our email newsletter
Patanol solution provides both mast cell stabilizing and anti-histamine properties in a single molecule, providing patients with rapid, effective and lasting relief from the signs and symptoms of allergic conjunctivitis, an allergen-induced inflammatory response characterized by ocular itching, redness and tearing.
Japan is the world’s second largest ocular allergy market and therefore represents a significant business opportunity for the company to expand sales of Patanol solution, according to Alcon Japan president Scott Manning.
“We anticipate launching this product in Japan this year and will be expanding our sales force to maximize this opportunity,” said Mr Manning. “We expect Patanol solution to be a contributor to our future growth.”
Patanol solution is approved in 83 countries, including the US, where it has become the leading product for the treatment of ocular allergy.